Serina Therapeutics initiated with a Buy at JonesResearch

JonesResearch analyst Justin Walsh initiated coverage of Serina Therapeutics (SER) with a Buy rating and $11 price target. Serina is a drug delivery and soon-to-be clinical stage biotech company that went public via a reverse merger with AgeX Therapeutics in March of last year whose lead asset, SER-252, is being developed for the management of motor fluctuations and dyskinesia in patients with advanced Parkinson’s Disease. The firm has “high confidence” that SER-252 will at least match the efficacy observed with other apomorphine delivery approaches, such as Supernus’ (SUPN) recently approved Onapgo, while delivering improved tolerability and convenience, the analyst tells investors.